{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-003026","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.427116+00:00","generated_at":"2026-05-28T02:58:09.179461+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protara reports positive TARA-002 NMIBC data; expects key milestones in 2025; cash runway into 2027","bullets":["TARA-002 in NMIBC: 72% CR at six months, 70% at any time; 100% maintained CR from 3 to 6 months; no Grade 2+ TRAEs.","Expects 12-month evaluable data mid-2025 and futility analysis of ~25 BCG-unresponsive patients by end 2025.","Expects to start THRIVE-3 registrational trial of IV Choline Chloride in 1H 2025; FDA Fast Track granted.","TARA-002 in LMs: initial results from additional STARBORN-1 cohorts expected by end of 1H 2025.","Cash of $81.5M plus ~$100M gross from December offering (including partial option exercise) funds operations into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-003026","json":"https://secwatch.observer/filing/0001213900-25-003026.json","markdown":"https://secwatch.observer/filing/0001213900-25-003026.md","text":"https://secwatch.observer/filing/0001213900-25-003026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/0001213900-25-003026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/ea0227457-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:58:09.179461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}